Duchenne UK and Parent Project Muscular Dystrophy Award $500,000 to Evaluate Safety and Tolerability of Muscle Progenitor Cells in Phase 1 Trial
The grant, totaling $500,000, will support Dr. Kang and his co-investigators in evaluating the safety and tolerability of muscle progenitor cells for Duchenne muscular dystrophy.
- The grant, totaling $500,000, will support Dr. Kang and his co-investigators in evaluating the safety and tolerability of muscle progenitor cells for Duchenne muscular dystrophy.
- Dr. Kang's project builds on previous research, utilizing muscle progenitor cells, known as MyoPAXon, developed by Dr. Rita Perlingeiro and her team at the University of Minnesota.
- This Phase 1 trial led by Dr. Kang's team will provide valuable insights into the safety and feasibility of transplanting MyoPAXon cells.
- Emily Reuben, Co-Founder and CEO of Duchenne UK, explains:
"Duchenne UK has supported Dr. Perlingeiro's work on developing muscle progenitor cells for a number of years.